PPM1D in Solid and Hematologic Malignancies: Friend and Foe?

por Zhang, Linda, Hsu, Joanne I., Goodell, Margaret A.
Publicado 2022

Proteasome Inhibitors Silence Oncogenes in Multiple Myeloma through Localized Histone Deacetylase 3 Stabilization and Chromatin Condensation

por Maneix, Laure, Iakova, Polina, Moree, Shannon E., Hsu, Joanne I., Mistry, Ragini M., Stossi, Fabio, Lulla, Premal, Sun, Zheng, Sahin, Ergun, Yellapragada, Sarvari V., Catic, André
Publicado 2022

PPM1D Mutations Drive Clonal Hematopoiesis in Response to Cytotoxic Chemotherapy

por Hsu, Joanne I., Dayaram, Tajhal, Tovy, Ayala, De Braekeleer, Etienne, Jeong, Mira, Wang, Feng, Zhang, Jianhua, Heffernan, Timothy P., Gera, Sonal, Kovacs, Jeffrey J., Marszalek, Joseph R., Bristow, Christopher, Yan, Yuanqing, Garcia-Manero, Guillermo, Kantarjian, Hagop, Vassiliou, George, Futreal, P. Andrew, Donehower, Lawrence A., Takahashi, Koichi, Goodell, Margaret A.
Publicado 2018

SOD1 is a synthetic lethal target in PPM1D-mutant leukemia cells

por Zhang, Linda, Hsu, Joanne I., Braekeleer, Etienne D., Chen, Chun-Wei, Patel, Tajhal D., Urya, Hidetaka, Guzman, Anna G., Martell, Alejandra G., Waldvogel, Sarah M., Tovy, Ayala, Callen, Elsa, Murdaugh, Rebecca, Richard, Rosemary, Jansen, Sandra, Vissers, Lisenka, de Vries, Bert B.A., Nussenzweig, Andre, Huang, Shixia, Coarfa, Cristian, Anastas, Jamie N., Takahashi, Koichi, Vassiliou, George, Goodell, Margaret A.
Publicado 2023

Lenalidomide promotes the development of TP53-mutated therapy-related myeloid neoplasms

por Sperling, Adam S., Guerra, Veronica A., Kennedy, James A., Yan, Yuanqing, Hsu, Joanne I., Wang, Feng, Nguyen, Andrew T., Miller, Peter G., McConkey, Marie E., Quevedo Barrios, Vanessa A., Furudate, Ken, Zhang, Linda, Kanagal-Shamanna, Rashmi, Zhang, Jianhua, Little, Latasha, Gumbs, Curtis, Daver, Naval, DiNardo, Courtney D., Kadia, Tapan, Ravandi, Farhad, Kantarjian, Hagop, Garcia-Manero, Guillermo, Futreal, P. Andrew, Ebert, Benjamin L., Takahashi, Koichi
Publicado 2022